Grifols SA (GIKLY) stock
Close on Oct 19, 2026Market cap $1.91BP/E 4.2Yield –
Grifols SA grew revenue 4.3% to €7.52B over fiscal 2025. Operating income rose 4.3% to €1.24B, moving the operating margin from 16.5% to 16.5%. Free cash flow was €782.00M, up 16.9% from a year earlier. At the latest close the market valued the company at €1.71B, 4.2 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- €1.71B
- P/E ratio
- 4.2
- Price to sales
- 0.23
- Price to book
- 0.32
- Dividend yield
- –
- Free cash flow yield
- 45.75%
Fundamentals
- Revenue
- €7.52B
- Net income
- €402.00M
- EPS, diluted
- 0.59 EUR
- Free cash flow
- €782.00M
Trading
- Previous close
- $5.55
- Open
- $5.55
- Day's range
- $5.55 – $5.55
- Volume
- 0
- Beta (5 years)
- 0.89
- RSI (14 days)
- 75.4
- Volatility (1 year)
- 32.5%
- Relative volume
- 1.59×
- WACC
- 10.6%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | GIKLY | S&P 500 | Difference | GIKLY per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.5% | +0.6% | −4.1 pts | ||
| 3 months | +8.8% | +3.4% | +5.4 pts | ||
| Year to date | -9.1% | +13.3% | −22.3 pts | ||
| 1 year | -18.2% | +16.6% | −34.8 pts | ||
| 3 years | -1.4% | +86.4% | −87.8 pts | -0.5% | +23.1% |
| 5 years | -53.7% | +81.9% | −135.6 pts | -14.3% | +12.7% |
| 10 years | -41.2% | +318.9% | −360.1 pts | -5.2% | +15.4% |
Twelve years at a glance
Fiscal years 2014 to 2025, EUR
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Grifols filed with the SEC as exhibits to Form 8-K or 6-K
About Grifols
Pharmaceutical Preparations
Grifols SA is a global healthcare company specializing in the development, manufacture, and distribution of plasma-derived therapies and related medical products. The company organizes its core business into segments covering biopharmaceuticals, diagnostics, and biological supplies. Its offerings include specialized therapeutic plasma derivatives, transfusion medicine systems, diagnostic instruments, and biological materials for healthcare applications. Grifols delivers these essential treatments and medical products primarily to hospitals, clinical laboratories, healthcare providers, and patients worldwide requiring critical plasma therapies.
Company profile, executives and historyGrifols stock: common questions
What is Grifols's stock price?
GIKLY closed at $5.55 on Oct 19, 2026, up 0.00% on the day.
What is Grifols's market cap?
Grifols was worth $1.91B at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is GIKLY's P/E ratio?
GIKLY trades at 4.2 times earnings, based on diluted earnings per share of 0.59 EUR over fiscal 2025.
How much revenue does Grifols make?
Grifols reported revenue of €7.52B for fiscal 2025, up 4.3% from a year earlier.
Does Grifols pay a dividend?
No. Grifols has not paid a cash dividend over the last twelve months.
How has GIKLY stock performed over the past year?
Including dividends, GIKLY returned -18.2% over the past year, against +16.6% for the S&P 500.
Who are Grifols's competitors?
Companies most similar to Grifols by business, industry and size include OGN, TEVA, VTRS, ONC, BHC.
See a number that looks wrong?